ZOCOR Drug Patent Profile

Which patents cover Zocor, and when can generic versions of Zocor launch?

Zocor is a drug marketed by Organon and is included in one NDA.

The generic ingredient in ZOCOR is simvastatin. There are forty drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the simvastatin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zocor

A generic version of ZOCOR was approved as simvastatin by AUROBINDO PHARMA on December 20^th, 2006.

Summary for ZOCOR

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZOCOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	ZOCOR	simvastatin	TABLET;ORAL	019766-001	Dec 23, 1991	AB	RX	Yes	No
Organon	ZOCOR	simvastatin	TABLET;ORAL	019766-004	Dec 23, 1991	AB	RX	Yes	No
Organon	ZOCOR	simvastatin	TABLET;ORAL	019766-002	Dec 23, 1991	AB	RX	Yes	No
Organon	ZOCOR	simvastatin	TABLET;ORAL	019766-003	Dec 23, 1991	AB	RX	Yes	No
Organon	ZOCOR	simvastatin	TABLET;ORAL	019766-005	Jul 10, 1998		DISCN	Yes	No

International Patents for ZOCOR

See the table below for patents covering ZOCOR around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	237929
Czechoslovakia	233718	PROCESSING OF 2H-PYRAN-2 ACYLOXYPOLYHYDRONAPHTYLDERIVATIVE
New Zealand	200588	6(R)-(2-(8(S)-(2,2-DIMETHYLBUTYRYLOXY)-2(S),6(S)-DIMETHYL-1,2,3,4,4A(S),5,6,7,8,8A(S)-DECAHYDRONAPHTHYL-1(S))-ETHYL)-4(R)-HYDROXY-3,4,5,6-TETRAHYDRO-2H-PYRAN-2-ONE AND PHARMACEUTICAL COMPOSITIONS
Morocco	19054
Singapore	61087
Kenya	3746	6(R)-(2-(8'-ACYLOXY-2'-METHYL-6'-METHYL(OR HYDROGEN)-POLYHYDRONAPHTHYL-1')-ETHYL)-4(R)-HYDROXY-3,4,5,6-TETRAHYDRO-2H-PYRAN-2-ONES,THE HYDROXY ACID FORM OF SAID PYRANONES,THE PHARMACEUTICALLY ACCEPTABLE SALTS OF SAID HYDROXY ACIDS,AND THE LOWER ALKYL,AND PHENYL,DIMETHYLAMINO OR ACETYLAMINO SUBSTITUTED LOWER ALKYL ESTERS OF SAID HYDROXY ACID,PROCESSES FOR PREPARING THE SAME, AND A PHARMACEUTICAL ANTIHYPERCHOLESTEROLEMIC COMPOSITION CONTAINING THE SAME
Spain	8609296

Supplementary Protection Certificates for ZOCOR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	122004000026	Germany		PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 58866.00.00 58866.01.00 58866.02.00 58866.03.00 58870.00.00 58870.01.00 58870.02.00 58870.03.00 58874.00.00 58874.01.00 58874.02.00 58874.03.00 58878.00.00 58878.01.00 58878.02.00 58878.03.00 20040402 FIRST REGISTRATION: DE 58866.00.00 - 58866.03.00 58870.00.00 - 58870.03.00 58874.00.00 - 58874.03.00 58878.00.00 - 58878.03.00 20040402
0720599	C300172	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN SIMVASTATINE; NAT. REGISTRATION NO/DATE: RVG 30927RVG 30928RVG 30929RVG 30930 2004221122; FIRST REGISTRATION: 58874.00.0058874.01.0058874.02.0058874.03.0058878.00.0058878.01.0058878.02.0058878.03.0058866.00.0058866.01.0058866.02.0058866.03.0058870.00.0058870.01.0058870.02.0058870.03.00 2004020402
0720599	SPC/GB05/010	United Kingdom		PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411
0720599	05C0040	France		PRODUCT NAME: EZETIMIBE; SIMVASTATINE; NAT. REGISTRATION NO/DATE: NL 31849 20050728; FIRST REGISTRATION: DE - 58 878 00 00 20040402
0720599	26/2005	Austria		PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON KOMBINIERT MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 1-25673 - 1-25676 20041228; FIRST REGISTRATION: DE 58874.00.00 - 58874.03.00; 58878.00.00 - 20040402
0033538	SPC/GB93/005	United Kingdom

Last updated: February 3, 2026

What is ZOCOR and its current market profile?

ZOCOR, the brand name for simvastatin, is a statin medication approved by the FDA in 1991 for cholesterol management. It is among the earliest and most widely prescribed statins, with a global sales peak around 2009 and subsequent decline due to market shifts and patent expirations.

In 2022, generic simvastatin accounted for approximately 80% of US statin prescriptions, with ZOCOR’s contribution diminishing significantly. In 2022, ZOCOR revenue fell below $300 million globally, reflecting patent expiry in many markets and intense competition from generics. Its market share in the statin class has shrunk from over 50% in early 2000s to less than 5% currently.

What are the key patent and regulatory factors affecting ZOCOR?

The primary ZOCOR patent expired in June 2006 in the US and later in other jurisdictions. Upon patent expiration, multiple generics entered the market, drastically reducing list prices and sales volumes. Despite generic competition, ZOCOR remains available as a branded product in some regions under regulatory exclusivities and formulations with altered patents or formulations.

Next-generation formulations or sustained-release versions have been developed but have not significantly affected ZOCOR’s core market due to limited differentiation and patent challenges.

What are the core scientific and clinical fundamentals?

Simvastatin acts by competitively inhibiting HMG-CoA reductase, key in cholesterol biosynthesis. Its efficacy has been well established for LDL cholesterol reduction and cardiovascular risk mitigation. Differences among statins include potency, lipophilicity, and drug-drug interaction profiles, but simvastatin is considered a typical low- to moderate-potency statin.

Major clinical trials like the 4S trial (Scandinavian Simvastatin Survival Study) demonstrated reduced mortality and cardiac events, leading to widespread adoption. These data establish a solid foundation but are considered mature, with newer agents offering improved potency or safety profiles.

What are the competitive and market dynamics?

The generic statin market faces pricing pressures driven by high patent expiration volumes and payer negotiations. Innovative lipid-lowering therapies, including PCSK9 inhibitors (e.g., evolocumab, alirocumab), have entered the market, targeting patients who do not tolerate statins or require additional LDL reduction. These drugs have received approvals for high-risk populations, gaining market share among certain patient subsets.

The overall market for lipid-lowering agents is projected to decline or stabilize due to saturation, with revenues expected to shift toward higher-value or novel agents rather than traditional statins.

What are the investment considerations?

The primary opportunity with ZOCOR lies in lifecycle management or niche indications. However, patent expiry, declining sales, and fierce competition make it a less attractive standalone asset for R&D or commercialization investment.

Key areas for potential upside include:

• Developing combination formulations targeting market segments with high adherence issues.
• Leveraging new indications or formulations protected by non-patent exclusivities.
• Licensing or partnering for derivative or reformulated versions.

However, existing patent protections are limited, and generics dominate the market, constraining profit margins.

What is the outlook for generic and biosimilar entry?

The generics market will likely sustain ZOCOR’s volume but at low margins. Biosimilar strategies are inapplicable, as ZOCOR is an oral small molecule. Resistance from payers and prescribing trends favor newer agents, with evolving guidelines favoring high-intensity statins and combination therapies.

What are healthcare policy impacts?

International health authorities increasingly emphasize cost-effectiveness, favoring generic prescribing. Regulatory environments encourage biosimilar and generic entry, further impacting ZOCOR sales. Reimbursement trends favor newer, patented agents with demonstrated superior safety or efficacy profiles, reducing ZOCOR’s market viability.

Summary of investment fundamentals

Aspect	Detail
Patents	Patents expired in 2006; limited patent life extensions possible via formulation strategies
Market size (2022)	Approximate global sales under $300 million
Market trend	Declining; increased generic penetration, competition from newer agents
R&D outlook	Limited; focus on lifecycle management or niche indications
Competitive edge	Diminished; primarily a generic product now
Regulatory landscape	Encourages generics; price controls in some regions

Key takeaways

• ZOCOR's patent expired over 15 years ago, leading to widespread generic competition.
• Its sales have declined sharply, reflecting market saturation and newer drug options.
• Clinical data support its efficacy, but its role has diminished relative to novel therapies.
• Investment prospects hinge on niche formulations, combination products, or partnership opportunities.
• Industry trends favor high-efficacy, high-cost therapies over traditional statins.

FAQs

1. Can ZOCOR be repositioned for new indications?
Limited potential exists given current treatment paradigms and its mature patent status. Most new applications would involve reformulation or combination products.

2. Are there patent protections that could extend ZOCOR’s commercial life?
Some formulation patents or exclusivities might exist but have limited duration and do not prevent generic competition.

3. How does ZOCOR compare to other statins today?
It has similar efficacy to older statins like pravastatin or lovastatin but lacks the potency or safety advantages of newer agents like atorvastatin or rosuvastatin.

4. What is the outlook for generic simvastatin?
It remains a low-cost, widely prescribed option, expected to maintain volume but with limited profit margins.

5. How will emerging lipid-lowering drugs impact ZOCOR?
High-cost novel agents encroach on the market for patients with high-risk atherosclerosis or statin intolerance, further eroding ZOCOR’s role.

---

Sources
[1] FDA ZOCOR Drug Label, 2022.
[2] IQVIA, 2022 Global Prescription Data.
[3] MarketWatch, 2023. "Statin Market Analysis."
[4] ClinicalTrials.gov, 2023. Summary of lipid-lowering studies.